Does orphan drug legislation really answer the needs of patients?

被引：56

作者：

Haffner, Marlene E. ^{[1
]}

Torrent-Farnell, Josep ^{[2
]}

Maher, Paul D. ^{[2
]}

机构：

[1] Amgen Corp, Washington, DC 20004 USA

[2] US FDA, Off Orphan Prod Dev, Rockville, MD 20857 USA

来源：

关键词：

D O I：

10.1016/S0140-6736(08)60873-9

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：2041 / 2044

页数：4

共 32 条

[1]

ANAND G, 2005, WALL STREET J 1116

[2]

Anand Geeta, 2005, Wall St J (East Ed), pA10

Arnon, Stephen S. .

Broder, S ;

Hotez, PJ .

[5]

Cheung Richard Y, 2004, Health Law J, V12, P183

[6]

*DEP HHS, 2001, ORPH DRUG ACT IMPL I

[7]

*FDA, MEFL HCL DES TREATM

[8]

*FDA, RIF DES TREATM PUL T

[9]

*FDA, QUIN SULF DES TREATM

[10]

*FDA, HAL DES TREATM AD WH